Luis Fernando Ng-Sueng

Luis Fernando Ng-Sueng

Auto-generated profile, based on publicly available information

Luis Fernando Ng-Sueng

Department of Internal Medicine, Henry Ford Health, Detroit, MI

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Alejandro PISCOYAAlejandro PISCOYA
Alejandro PISCOYA
LNLuis F. Ng-Sueng
Luis F. Ng-Sueng
ARAngela Parra del Riego
Angela Parra del Riego
RCRenato Cerna-Viacava
Renato Cerna-Viacava
VPVinay Pasupuleti
Vinay Pasupuleti
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
Background: Efficacy and safety of treatments for hospitalized COVID-19 are uncertain. We systematically reviewed efficacy and safety of remdesivir for the treatment of COVID-19. Methods: Studies evaluating remdesivir in adults with hospitalized COVID-19 were searched in several engines until August 21, 2020. Primary outcomes included all-cause mortality, clinical improvement or recovery, need for invasive ventilation, and serious adverse events (SAEs). Inverse variance random effects meta-analyses were performed. Results: We included four randomized controlled trials (RCTs) (n = 2296) [two vs. placebo (n = 1299) and two comparing 5-day vs. 10-day regimens (n = 997)], and two case series (n = 88). Studies used intravenous remdesivir 200mg the first day and 100mg for four or nine more days. One RCT (n = 236) was stopped early due to AEs; the other three RCTs reported outcomes between 11 and 15 days. Time to recovery was decreased by 4 days with remdesivir vs. placebo in one RCT (n = 1063), and by 0.8 days with 5-days vs. 10-days of therapy in another RCT (n = 397). Clinical improvement was better for 5-days regimen vs. standard of care in one RCT (n = 600). Remdesivir did not decrease all-cause mortality (RR 0.71, 95%CI 0.39 to 1.28, I2 = 43%) and need for invasive ventilation (RR 0.57, 95%CI 0.23 to 1.42, I2 = 60%) vs. placebo at 14 days but had fewer SAEs; 5-day decreased need for invasive ventilation and SAEs vs. 10-day in one RCT (n = 397). No differences in all-cause mortality or SAEs were seen among 5-day, 10-day and standard of care. There were some concerns of bias to high risk of bias in RCTs. Heterogeneity between studies could be due to different severities of disease, days of therapy before outcome determination, and how ordinal data was analyzed. Conclusions: There is paucity of adequately powered and fully reported RCTs evaluating effects of remdesivir in hospitalized COVID-19 patients. Until stronger evidence emerges, we cannot conclude that remdesivir is efficacious for treating COVID-19.

12 August 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LNLuis Fernando Ng-Sueng
Luis Fernando Ng-Sueng
IVIván Vargas-Matos
Iván Vargas-Matos
PMPercy Manuel Mayta-Tristán
Percy Manuel Mayta-Tristán
RPReneé Pereyra-Elías
Reneé Pereyra-Elías
JMJuan José Montenegro-Idrogo
Juan José Montenegro-Idrogo
RLRed Lirhus
Red Lirhus
The selection of a medical specialty has been associated with multiple factors, such as personal preferences, academic exposure, motivational factors and sociodemographic factors, such as gender. The number of women in the medical field has increased in recent years. In Latin America, we have not found any studies that explore this relationship. To determine whether there is an association between gender and the intention to choose a medical specialty in medical students from 11 countries in Latin America. Secondary analysis of the Collaborative Working Group for the Research of Human Resources for Health (Red-LIRHUS) data; a multi-country project of students in their first year and fifth year of study, from 63 medical schools in 11 Latin American countries. All students who referred intention to choose a certain medical specialty were considered as participants. Of the 11073 surveyed students, 9235 indicated the name of a specific specialty. The specialties chosen most often in the fifth year were General Surgery (13.0%), Pediatrics (11.0%), Internal Medicine (10.3%) and Obstetrics/Gynecology (9.0%). For women, the top choices were Pediatrics (15.8%), Obstetrics/Gynecology (11.0%), Cardiology (8.7%), General Surgery (8.6%), and Oncology (6.4%). In the adjusted analysis, the female gender was associated with the choice of Obstetrics/Gynecology (RP: 2.75; IC95%: 2.24–3.39); Pediatric Surgery (RP: 2.19; IC95%: 1.19–4.00), Dermatology (RP: 1.91; IC95%:1.24–2.93), Pediatrics (RP: 1.83; IC95%: 1.56–2.17), and Oncology (RP: 1.37; IC95%: 1.10–1.71). There is an association between the female gender and the intention to choose Obstetrics/Gynecology, Pediatrics, Pediatric Surgery, Dermatology, and Oncology. We recommend conducting studies that consider other factors that can influence the choice of a medical specialty.

1 December 2012 in Revista Peruana de Medicina Experimental Y Salud Pública
Verified
Journal Article
Open access
PDF file
MTMiguel Toro-Polo
Miguel Toro-Polo
RPReneé Pereyra-Elías
Reneé Pereyra-Elías
ANAyar Nizama-Vía
Ayar Nizama-Vía
LNLuis Fernando Ng-Sueng
Luis Fernando Ng-Sueng
EVEduardo Vélez-Segovia
Eduardo Vélez-Segovia
PMPercy Mayta-Tristán
Percy Mayta-Tristán
To determine the publication rate of abstracts submitted at the national scientific meetings of medical students in Peru between 2002 and 2009, and associated factors. A retrospective cohort was performed; the characteristics of overall abstract submitted were assessed. In addition, whether they were published in scientific journals was determined by way of a search strategy validated using Google Scholar. Crude and adjusted relative risks (RR) were calculated using Poisson regression with robust variance to assess association with the analyzed factors. 532 abstracts were analyzed, 52 (9.8%) of which were published in scientific journals after their presentation at a scientific meeting. All of them were published in Peruvian journals written in Spanish. The most important journal in which they were published was Ciencia e Investigación Médica Estudiantil Latinoamericana (CIMEL) (13/52). The median of publication time was 13 months (range: 0-75). The fact that a student from the Universidad Nacional Mayor de San Marcos (RR: 5.18; CI95%:2.3-11.6) is the author of the abstract and that the abstract was collaboratively written by students from two universities (RR: 3.64; CI95%:1.1-11.7) are associated factors in the multivariate analysis. The publication rate of abstract submitted at national scientific meetings of medical students in Peru is low. New strategies should be taken, and the existing ones should be reinforced in order to increase the publication rate of the abstract submitted.

27 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
Alejandro PISCOYAAlejandro PISCOYA
Alejandro PISCOYA
LNLuis Fernando Ng-Sueng
Luis Fernando Ng-Sueng
ARAngela Parra del Riego
Angela Parra del Riego
RCRenato Cerna-Viacava
Renato Cerna-Viacava
VPVinay Pasupuleti
Vinay Pasupuleti
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
Background: We evaluated the efficacy and safety of remdesivir for the treatment of COVID-19. Methods: Systematic review in five engines, pre-print webpages and RCT registries until May 22, 2020 for randomized controlled trials (RCTs) and observational studies evaluating remdesivir on confirmed, COVID-19 adults with pneumonia and/or respiratory insufficiency. Primary outcomes were all-cause mortality, clinical improvement or recovery, need for invasive ventilation, and serious adverse events (SAE). Secondary outcomes included length of hospital stay, progression of pneumonia, and adverse events (AE). Inverse variance random effects meta-analyses were performed. Results: Two placebo-controlled RCTs (n=1300) and two case series (n=88) were included. All studies used remdesivir 200mg IV the first day and 100mg IV for 9 more days, and followed up until 28 days. Wang et al. RCT was stopped early due to AEs; ACTT-1 was preliminary reported at 15-day follow up. Time to clinical improvement was not decreased in Wang et al. RCT, but median time to recovery was decreased by 4 days in ACTT-1. Remdesivir did not decrease all-cause mortality (RR 0.71, 95%CI 0.39 to 1.28) and need for invasive ventilation at 14 days (RR 0.57, 95%CI 0.23 to 1.42), but had fewer SAEs (RR 0.77, 95%CI 0.63 to 0.94). AEs were similar between remdesivir and placebo arms. Risk of bias ranged from some concerns to high risk in RCTs. Interpretation: There is paucity of adequately powered and fully reported RCTs evaluating effects of remdesivir in adult, hospitalized COVID-19 patients. Remdesivir should not be recommended for the treatment of severe COVID-19.

4 August 2021 in Archives of Medical Science
Verified
Journal Article
Open access
Alejandro PISCOYAAlejandro PISCOYA
Alejandro PISCOYA
LNLuis Fernando Ng-Sueng
Luis Fernando Ng-Sueng
ARAngela Parra del Riego
Angela Parra del Riego
RCRenato Cerna-Viacava
Renato Cerna-Viacava
VPVinay Pasupuleti
Vinay Pasupuleti
Adrian V. HernandezAdrian V. Hernandez
Adrian V. Hernandez
Introduction: We systematically reviewed benefits and harms of convalescent plasma (CP) in hospitalized COVID-19 patients.Material and methods: Randomized controlled trials (RCTs) and observational studies assessing CP effects on hospitalized, adult COVID-19 patients were searched until November 24, 2020. We assessed risk of bias (RoB) using Cochrane RoB 2.0 and ROBINS-I tools. Inverse variance random effect meta-analyses were performed. Quality of evidence was evaluated using GRADE methodology. Primary outcomes were all-cause mortality, clinical improvement, and adverse events.Results: Five RCTs (n = 1067) and 6 cohorts (n = 881) were included. Three and 1 RCTs had some concerns and high RoB, respectively; and there was serious RoB in all cohorts. Convalescent plasma did not reduce all-cause mortality in RCTs of severe (RR = 0.60, 95% CI: 0.33–1.10) or moderate (RR = 0.60, 95% CI: 0.09–3.86) COVID-19 vs. standard of care (SOC); CP reduced all-cause mortality vs. SOC in cohorts (RR = 0.66, 95% CI: 0.49–0.91). Convalescent plasma did not reduce invasive ventilation vs. SOC in moderate disease (RR = 0.85, 95% CI: 0.47–1.55). In comparison to placebo + SOC, CP did not affect all-cause mortality (RR = 0.75, 95% CI: 0.48–1.16) or clinical improvement (HR = 1.07, 95% CI: 0.82–1.40) in severe patients. Adverse and serious adverse events were scarce, similar between CP and controls. Quality of evidence was low or very low for most outcomes.Conclusions: In comparison to SOC or placebo + SOC, CP did not reduce all-cause mortality in RCTs of hospitalized COVID-19 patients. Convalescent plasma did not have an effect on other clinical or safety outcomes. Until now there is no good quality evidence to recommend CP for hospitalized COVID-19 patients.

24 September 2015
Verified
Journal Article
Closed access
IVIván Vargas-Matos
Iván Vargas-Matos
LNLuis Fernando Ng-Sueng
Luis Fernando Ng-Sueng
JFJoel Flores-Arriaga
Joel Flores-Arriaga
SBSantiago Beltrán-Flores
Santiago Beltrán-Flores
MLMauricio Lema-Correa
Mauricio Lema-Correa
PMPercy Manuel Mayta-Tristán
Percy Manuel Mayta-Tristán